Previous close | 65.05 |
Open | 65.50 |
Bid | 65.80 x 0 |
Ask | 65.95 x 0 |
Day's range | 65.50 - 65.50 |
52-week range | 15.43 - 67.85 |
Volume | |
Avg. volume | 674 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.